Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox for neurofunctional repair after aneurysmal subarachnoid hemorrhage
ChiCTR2400088318Phase 3Recruiting
- Sponsor
- Yuebei People's Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) and brain aneurysm (IA) comparing Deferasirox intervention arm with Normal saline placebo arm (2 arms). Primary endpoint: Cognitive function and independence (MoCA and modified Rankin Scale). Started Jul 2025; status: recruiting.
02
Drugs
deferasirox
03
Conditions
subarachnoid hemorrhage (SAH)brain aneurysm (IA)
Beyond the preview
Go deeper on ChiCTR2400088318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088318.